Combined immunotargeted therapy as an effective treatment of platinoresistent recurrent / metastatic squamous cell head and neck cancer

Cover Page

Cite item

Full Text

Abstract

Treatment of head and neck squamous cell carcinoma remains a global oncological problem. This pathology is the 7th most common oncological disease in the world. According to the Cancer Statistics 2024 global registry, more than 900,000 new cases of this disease and approximately 450,000 associated deaths are registered annually which highlights tumor aggressiveness and treatment difficulty. Despite the successes in diagnosis of malignant tumors, in more than 80 % of patients head and neck squamous cell carcinoma is diagnosed at stages III–IV because of non-specific disease symptoms at stages I–II. Traditional treatment methods (surgical intervention, radiotherapy, and chemotherapy) often allow to achieve complete recovery in patients with early-stage disease. However, in the majority of tumor recurrences, efficacy of these approaches is limited, and their use is associated with significant adverse events. Considering the high rate of progression of recurrence platinum-refractory head and neck squamous cell carcinoma after standard antitumor regimens, the search for new, more effective approaches to treatment remain necessary.

The article presents our own clinical experience of successful treatment of patients with recurrent platinum-refractory head and neck squamous cell carcinoma using combination immunotherapy and targeted therapy with cetuximab and anti-PD-1 inhibitor (PD-1 – programmed cell death receptor 1).

About the authors

A. M. Mudunov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Author for correspondence.
Email: mbpak@yandex.ru
ORCID iD: 0000-0002-0918-3857
Russian Federation, 111 1st Uspenskoe Shosse, Lapino, Moscow Region 143081; Bld. 2, 8 Trubetskaya St., Moscow 119991

M. B. Pak

Specialized Medical Center of the Bank of Russia

Email: mbpak@yandex.ru
ORCID iD: 0000-0003-4546-0011
Russian Federation, 66 Sevastopolsky Prospekt, 116152 Moscow

A. M. Khabazovа

Specialized Medical Center of the Bank of Russia

Email: mbpak@yandex.ru
ORCID iD: 0000-0001-9372-3328
Russian Federation, 66 Sevastopolsky Prospekt, 116152 Moscow

References

  1. Bray F., Laversanne M., Sung H. et al. Global Cancer Statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–63.
  2. Kakurina G.V., Kondakova I.V., Choĭnzonov E.L. Prognosis for the metastasis of squamous cell carcinoma of the head and neck. Voprosy onkologii = Voprosy Onkologii 2012;58(1):26–32. (In Russ.).
  3. Bernier J., Cooper J.S., Pajak T.F. et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005;27(10):843–50. doi: 10.1002/hed.20279
  4. Machiels J.P., René Leemans C., Golusinski W. et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines. Ann Oncol 2020;31(11):1462–75. doi: 10.1016/j.annonc.2020.07.011
  5. Leon X., Quer M., Orus C. et al. Distant metastases in head and neck cancer patients who achieved loco-regional control. Head Neck 2000;22(7):680–6. doi: 10.1002/1097-0347(200010)22:7<680::aid-hed7>3.0.co;2-j
  6. Al Maqrashi Z., Bradbury M., Chan S.W.S. et al. Prognostic factors in advanced incurable HNSCC patients on palliative-intent immunotherapy-based regimen. Future Sci OA 2025;11(1):2552067. doi: 10.1080/20565623.2025.2552067
  7. Akolkar D., Patil D., Crook T. et al. Circulating tumor associated cells in head and neck cancers are resistance educated per previous chemotherapy treatments. Int J Radiat Oncol Biol Phys 2020;106(5):1121. doi: 10.1016/j.ijrobp.2019.11.375
  8. Bonner J.A., Harari P.M., Giralt J. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567–78. doi: 10.1056/NEJMoa053422
  9. Vermorken J.B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116–27. doi: 10.1056/NEJMoa0802656
  10. Guigay I., Anne Aupérin A., Fayette J. et. al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2021;22(4):463–75. doi: 10.1016/S1470-2045(20)30755-5
  11. Ferris R.L., Blumenschein G. Jr, Fayette J. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856–67. doi: 10.1056/NEJMoa1602252
  12. Burtness B., Harrington K.J., Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915–28. doi: 10.1016/S0140-6736(19)32591-7
  13. Cohen E.E.W., Soulières D., Le Tourneau C. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156–67. doi: 10.1016/S0140-6736(18)31999-8
  14. Chung C.H., Bonomi M., Steuer C.E. et al. Concurrent cetuximab and nivolumab as a second-line or beyond treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results of phase I/II study. Cancers 2021;13:1180. doi: 10.3390/cancers13051180
  15. Sacco A.G., Ruifeng Chen R., Worden F.P. et al. Lancet Oncol 2021;22(6):883–92. doi: 10.1016/S1470-2045(21)00136-4
  16. Tian X., Zhang H., Han Y. et. al. Current status and future prospects of combined immunotherapy and epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma. Cancer Treat Rev 2025;132:102864. doi: 10.1016/j.ctrv.2024.102864

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 Mudunov A.M., Pak M.B., Khabazovа A.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36990 от  21.07.2009.